15 assets in Inflammatory Bowel Disease

Therapeutic assets addressing Inflammatory Bowel Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Macrogols Inflammatory Bowel Disease	Region Skane	P4	A (81)
Prucalopride Inflammatory Bowel Disease	Region Skane	P4	BBB (73)
Gastrografin Inflammatory Bowel Disease	Region Skane	P3	BB (64)
Sodium Phosphate Inflammatory Bowel Disease	Region Skane	P3	BB (64)
Sodium Picosulfate Inflammatory Bowel Disease	Region Skane	P3	BB (64)
Vancomycin Inflammatory Bowel Disease	Tampere University Hospital	P2	B (60)
Human Faecal Matter Inflammatory Bowel Disease	University of Birmingham	P2	CCC (53)
Mirtazapine Inflammatory Bowel Disease	King's College London	P2	CCC (53)
Sgm-101 Inflammatory Bowel Disease	Leiden University Medical Center	P2	CCC (53)
Cabozantinib Inflammatory Bowel Disease	National Cancer Institute (NCI)	P1	CC (43)
Ipilimumab Inflammatory Bowel Disease	National Cancer Institute (NCI)	P1	CC (43)
Nivolumab Inflammatory Bowel Disease	National Cancer Institute (NCI)	P1	CC (43)
Rosuvastatin Inflammatory Bowel Disease	Stanford University	Early P1	C (39)
Nabilone Inflammatory Bowel Disease	Samuel Lunenfeld Research Institute, Mount Sinai Hospital	N/A	D (30)